Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2009-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/JCP.0b013e3181acc4ddPMID 19593180
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers

  2009cited by this paper
• Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics

  2008cited by this paper
• Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele

  2008cited by this paper
• Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

  2007cited by this paper
• Cytochrome P450 2D6 genotype variation and venlafaxine dosage.

  2007cited by this paper
• CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

  2006cited by this paper
• Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

  2006cited by this paper
• An overview of psychotropic drug-drug interactions.

  2005cited by this paper
• CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study

  2004cited by this paper
• Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine

  2003cited by this paper
• Venlafaxine serum levels and CYP2D6 genotype.

  2000cited by this paper
• O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants

  1999cited by this paper
• Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.

  1999influential reference
• Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

  1999cited by this paper
• Venlafaxine oxidation in vitro is catalysed by CYP2D6.

  1996cited by this paper
• Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite

  1992cited by this paper
• Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

  1985cited by this paper
• Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation

  1985cited by this paper
• Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

  1979cited by this paper
• Polymorphic hydroxylation of Debrisoquine in man.

  1977cited by this paper
• Letter: Neutrophil function and myeloperoxidase activity in inflammatory bowel disease.

  1976cited by this paper

• Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths

  2024cites this paper
• Can the Publication of Case Series or Case Reports Lead to a Change in Clinical Practice?

  2023cites this paper
• UKnowledge UKnowledge

  2022cites this paper
• Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype

  2021cites this paper
• Therapeutic Drug Monitoring of Antidepressants.

  2019cites this paper
• Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.

  2019cites this paper
• Effect of human pharmaceuticals common to aquatic environments on hepatic CYP1A and CYP3A-like activities in rainbow trout (Oncorhynchus mykiss): An in vitro study.

  2018cites this paper
• Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.

  2018cites this paper
• The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis

  2018cites this paper
• Quantitation of escitalopram and its metabolites by liquid chromatography‐tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment

  2018cites this paper
• Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

  2018cites this paper
• Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

  2017cites this paper
• What is the role of CYP genotyping in psychiatry?

  2017cites this paper
• Effect of CYP2D6 variants on venlafaxine metabolism in vitro

  2016influential citation
• Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry

  2016cites this paper
• Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype

  2016cites this paper
• Optimizing treatment with psychotropic agents through precision drug therapy

  2016cites this paper
• Genetic Polymorphisms of Cytochrome P450 and Antidepressants

  2016cites this paper
• Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications

  2015cites this paper
• PharmGKB summary: venlafaxine pathway

  2014cites this paper
• Distribution of Venlafaxine, O‐desmethylvenlafaxine, and O‐desmethylvenlafaxine to Venlafaxine Ratio in Postmortem Human Brain Tissue

  2014cites this paper
• Are there meaningful biomarkers of treatment response for depression?

  2014cites this paper
• Prediction of individual response to antidepressants and antipsychotics: an integrated concept

  2014cites this paper
• Clinical applications of CYP genotyping in psychiatry

  2014cites this paper
• Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences

  2014cites this paper
• Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers

  2014influential citation
• An observational study of Venlafaxine and CYP2D6 in clinical practice.

  2014cites this paper
• Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man.

  2014cites this paper
• First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma.

  2014cites this paper
• Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

  2013cites this paper
• Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

  2013cites this paper
• How Pharmacogenomics (PG) Are Changing Practice: Implications for Prescribers, Their Patients, and the Healthcare System (PG Series Part I)

  2013cites this paper
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cites this paper
• Therapeutic monitoring of psychoactive drugs - antidepressants: a review.

  2013cites this paper
• Phenoconversion of cytochrome P450 2D6: the need for identifying the intermediate metabolizer genotype.

  2013cites this paper
• Biotransformation pathways of biocides and pharmaceuticals in freshwater crustaceans based on structure elucidation of metabolites using high resolution mass spectrometry.

  2013cites this paper
• Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

  2013cites this paper
• A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression

  2012cites this paper
• Clinically Significant Drug Interactions with Newer Antidepressants

  2012cites this paper
• Metabolism of Psychotropic Drugs

  2012cites this paper
• Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP 2 D 6 Extensive and Poor Metabolizers A Randomized , Open-Label , Two-Period , Parallel-Group , Crossover Study

  2012cites this paper
• Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

  2011cites this paper
• A post-mortem database study

  2011cites this paper
• Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?

  2011cites this paper
• Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.

  2011cites this paper
• CYP 2D6 PM Status and Antidepressant Response to Nortriptyline and Venlafaxine: Is It More Than Just Drug Metabolism?

  2011cites this paper
• Drug epidemiology, interactions and pharmacogenetics : A post-mortem database study

  2011cites this paper
• Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers

  2011cites this paper
• Understanding Outliers on the Usual Dose-Response Curve: Venlafaxine as a Way to Phenotype Patients in Terms of Their CYP 2D6 Status and Why It Matters

  2010cites this paper
• Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

  2010cites this paper
• Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

  2010cites this paper
• Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.

  2010cites this paper